trial · primary record
LYL273
Colorectal Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 155 |
| Primary completion | 2032-06 |
| Primary endpoint | Phase 1: Incidence of adverse events (AEs) defined as dose-limiting toxicities (DLTs) during 3+3 dose escalation study |
| Registry ID | NCT05319314 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:45:16.759Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05319314
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.